Document:

Exhibit 10.25

 EXHIBIT 10.25 
  

	
	2010 PERFORMANCE OBJECTIVES – CEO AND PRESIDENT

  
  
 TARGET BONUS AS A PERCENTAGE OF BASE SALARY 
 The 2010 target bonus for the Chief Executive Officer (“CEO”) of Allergan, Inc. (the “Company”) will be an amount equal to 130% of the CEO’s annual base salary as of
the last day of the 2010 fiscal year. The 2010 target bonus for the President of the Company (“President”) will be an amount equal to 77% of the President’s annual base salary as of the last day of the 2010 fiscal year. The
2010 target bonus amounts for the CEO and the President are referred to herein individually as a “Target Bonus Amount” and collectively as the “Target Bonus Amounts.” 
  
  
 2010 PERFORMANCE OBJECTIVES AND BONUS AMOUNT DETERMINATION 
 If the
Company’s 2010 Adjusted EPS is greater than the Threshold EPS, the CEO and President will be eligible to receive a bonus based on the following three criteria: (i) 2010 Adjusted EPS, (ii) 2010 Revenue Growth and (iii) 2010
R&D Reinvestment Rate. The bonus (if any) payable will be an amount determined by multiplying (i) the Target Bonus Amount by (ii) the Target Bonus Multiplier. In no event, however, will the CEO or President be eligible to receive all
or any portion of such bonus if the Company’s 2010 Adjusted EPS does not exceed the Threshold EPS. For sake of clarity, if the Company’s performance exceeds any of the targets for 2010 Revenue Growth and/or 2010 R&D Reinvestment Rate,
but actual 2010 Adjusted EPS does not exceed the Threshold EPS, no bonus will be payable. Payment of the CEO’s and President’s 2010 performance bonus (if any) will be made in accordance with, and subject to, the terms of the Allergan, Inc.
2006 Executive Bonus Plan, as in effect on the date hereof (the “Plan”), including, without limitation, the provisions of Sections 2.4, 3.3 and 6.3 of the Plan. 
 For purposes of determining the CEO’s and President’s 2010 performance bonus, the following terms will have the following meanings: 
 “2010 Adjusted EPS” means the Company’s 2010 Adjusted Net Earnings divided by the weighted average
number of common shares outstanding on a diluted basis during 2010, rounded to the fourth decimal place. 
 “2010 Adjusted Net Earnings” means the Company’s net earnings from continuing operations for the 2010 fiscal year, adjusted to: 
  

	 	•	 	 remove the effects of extraordinary, unusual or non-recurring items; 

  

	 	•	 	 remove the effects of items that are outside the scope of the Company’s core, on-going business activities; 

  

	 	•	 	 remove the effects of accounting changes required by United States generally accepted accounting principles; 

  

	 	•	 	 remove the effects of financing activities; 

  

	 	•	 	 remove the effects of expenses for restructuring or productivity initiatives; 

  

	 	•	 	 remove the effects of non-operating items; 

  

	 	•	 	 remove the effects of spending for acquisitions; 

  

	 	•	 	 remove the effects of divestitures; and 

  

	 	•	 	 remove the effects of amortization of acquired intangible assets. 

  

  
 1 

			
	 2010 PERFORMANCE OBJECTIVES
	  	ALLERGAN, INC.

  
  
 “2010 Revenue
Growth” means the percentage increase (if any) in net product sales for the 2010 fiscal year relative to net product sales for the 2009 fiscal year, adjusted for the translation effect of changes in foreign exchange rates between each
fiscal year, rounded to the nearest one-hundredth of one percent. 
 “2010 R&D Reinvestment
Rate” means total research and development expenses for the 2010 fiscal year as a percentage of the Company’s total net sales, for the 2010 fiscal year, rounded to the nearest one-hundredth of one percent. 
 “EPS Target” means an amount per share specified by the Organization and Compensation Committee at the time
of adoption of these performance objectives. 
 “Target Bonus Multiplier” means the sum of the
“% of Target Bonus Amount” corresponding to: (a) the Company’s 2010 Adjusted EPS, (b) the Company’s 2010 Revenue Growth, and (c) the Company’s 2010 R&D Reinvestment Rate, in each case as determined in
accordance with the tables set forth on Exhibit A. 
 “Threshold EPS” means the EPS
Target, less $0.15. 
  
  
 2010 METHOD OF BONUS PAYMENT 
 Bonuses will be paid in cash up to a maximum bonus pool equal to 100% of Plan participants’ bonus targets. Bonuses will be paid in restricted stock or restricted stock units to the extent the bonus
pool exceeds 100% of Plan participants’ bonus targets. Such restricted stock or restricted stock units will provide for cliff vesting two years from the award effective date. Any payment in the form of restricted stock or restricted stock units
will be issued under the Company’s 2008 Incentive Award Plan. Subject to the terms of the 2008 Incentive Award Plan, upon a recipient’s death or Total Disability (as defined below), or upon a recipient’s Normal Retirement Eligibility
Date (as defined below), all of the restrictions imposed on the recipient’s restricted stock or restricted stock units shall lapse. For purposes of the foregoing, (i) “Total Disability” has the meaning set forth in
Section 22(e)(3) of the Internal Revenue Code (generally defined as the inability of a recipient, by reason of mental or physical illness, to perform any substantial gainful activity, which disability is expected to result in death or continue
for a period of at least 12 months) and (ii) a recipient’s “Normal Retirement Eligibility Date” means the date on which the recipient has (a) attained age 55 and (b) been employed by the Company for a minimum of 5
years. 
  

  
 2 

			
	 2010 PERFORMANCE OBJECTIVES
	  	ALLERGAN, INC.

  
  
 EXHIBIT A 
 TO 
 2010
PERFORMANCE OBJECTIVES – CEO AND PRESIDENT 
 2010 ADJUSTED EPS, 2010 REVENUE GROWTH AND 
 2010 R&D REINVESTMENT RATE PERFORMANCE 
  
  
  
  

																	
	  
 Earnings Per Share
  
	  		 	  
 Revenue Growth
  
	  		 	  
 R&D Reinvest Rate
  

	 EPS Range %
  
	  	 EPS Range
  
	 	  
 Bonus % of
 Target
  
	  		 	  
 Revenue Growth
  
	 	  
 Bonus % of
 Target
  
	  		 	  
 ~R&D Reinvest Rate
  
	 	  
 Bonus % of
 Target
  

	 		 		 	 		 	 
	 -4.8%
	  	-$0.150	 	  0.0%	  		 		 	 	  		 		 	 
	 		 		 	 		 	 
	 -2.6%
	  	-$0.080	 	46.0%	  		 	0.4%	 	  0.0%	  		 	14.75%	 	  0.0%
	 		 		 	 		 	 
	 -2.2%
	  	-$0.070	 	57.0%	  		 	1.4%	 	  2.0%	  		 	15.00%	 	  2.0%
	 		 		 	 		 	 
	 -1.4%
	  	-$0.045	 	68.0%	  		 	2.4%	 	  4.0%	  		 	15.25%	 	  4.0%
	 		 		 	 		 	 
	 -1.1%
	  	-$0.035	 	72.0%	  		 	3.4%	 	  6.0%	  		 	15.50%	 	  6.0%
	 		 		 	 		 	 
	 -0.6%
	  	-$0.020	 	76.0%	  		 	4.4%	 	  8.0%	  		 	15.75%	 	  8.0%
	 		 		 	 		 	 
	 	  	Target	 	80.0%	  		 	5.4%	 	10.0%	  		 	16.00%	 	10.0%
	 		 		 	 		 	 
	  1.0%
	  	 $0.030	 	84.0%	  		 	6.4%	 	13.8%	  		 	16.25%	 	13.8%
	 		 		 	 		 	 
	  1.9%
	  	 $0.060	 	88.0%	  		 	7.4%	 	17.5%	  		 	16.50%	 	17.5%
	 		 		 	 		 	 
	  2.6%
	  	 $0.080	 	92.0%	  		 	8.4%	 	21.3%	  		 	16.75%	 	21.3%
	 		 		 	 		 	 
	  3.2%
	  	 $0.100	 	96.0%	  		 	9.4%	 	25.0%	  		 	17.00%	 	25.0%

 If the Company’s performance exceeds the highest performance level shown above for one or more of the specified performance measures (i.e., 2010 Adjusted EPS, 2010
Revenue Growth, and 2010 R&D Reinvestment Rate), the “% of Target Bonus Amount” achieved with respect to that performance measure will be the maximum “% of Target Bonus Amount” specified for that performance measure. For
example, if 2010 Adjusted EPS equals EPS Target + $0.11, the “% of Target Bonus Amount” will nonetheless be 96% for that performance measure. 
 If actual results for any one or more of the performance measures falls between the performance levels shown above, the bonus will be prorated accordingly. 
 Each component of the Target Bonus Multiplier will be determined independently of each other component of the Target Bonus Multiplier;
provided that no bonus will be payable in the event the Company’s 2010 Adjusted EPS does not exceed the Threshold EPS. 
  

  
 3Exhibit 10.26

 EXHIBIT 10.26 
 A L L E R G A N 
  

	
	  
 2010
  
 M A N A G E M E NT  B O N U S   P L A N
  

  
  
  
  
  
  

  
  

  
 PURPOSE
OF THE PLAN 
 The Allergan, Inc. 2010 Management Bonus Plan (the “Plan”) is designed to reward eligible
management-level employees for their contributions to providing Allergan’s stockholders increased value for their investment through the successful accomplishment of specific financial objectives and individual performance objectives.

  
  
 PLAN YEAR 
 The Plan year runs from January 1, 2010 through
December 31, 2010. 
  
  
 ELIGIBILITY 
 Unless otherwise
provided in a written agreement between the Company and the applicable employee, and subject to the terms of the Plan, each regular full-time and part-time employee of Allergan, Inc. and its subsidiaries (collectively, the “Company”) in
salary grades 7E and above who is scheduled to work 20 or more hours per week and who is not covered by any other bonus or sales incentive plan is eligible to participate in the Plan. Notwithstanding anything in this Plan to the contrary, any
individual who (a) performs services for the Company and is classified or paid as an independent contractor (regardless of his or her classification for federal tax or other legal purposes) by the Company or (b) performs services for the
Company pursuant to an agreement between the Company and any other person or entity (e.g. a leasing organization) shall not be eligible to participate in the Plan. In addition, in order to be eligible to receive a bonus, an employee must be employed
by the Company on or before June 30, 2010 and must be actively employed by the Company on the date bonuses are paid. Any employee who resigns or is terminated for reasons other than those noted below will receive no bonus. 
 Bonuses, if any, will be prorated for any participant who (i) becomes eligible to participate in the Plan after the beginning of the
Plan year, (ii) retires on or after his or her “normal retirement” date (“normal retirement” is defined as termination of employment after the Plan participant has attained age 55, provided that such participant has been
employed by the Company for a minimum of 5 years), (iii) becomes disabled, (iv) dies or (v) transfers into a position covered by another incentive plan. Notwithstanding the foregoing, a participant will receive no bonus in cases of
normal retirement or termination that, in either case, the Company determines in its sole discretion to be (a) by mutual agreement, (b) during counseling review, (c) after counseling review or (d) for serious misconduct. Bonuses,
if any, for any participant who is laid-off will be prorated provided the participant was eligible to participate in the Plan for at least six months of the Plan year. All proration will be based on the number of months of participation in the Plan
during the Plan year. 
  
  
 PERFORMANCE OBJECTIVES 
 Bonuses
under the Plan are determined based on both corporate performance and individual performance in relation to pre-established objectives, as follows: 
 CORPORATE OBJECTIVES 

	 	¿	 	 Earnings Per Share (“EPS”)—EPS is defined as adjusted net earnings from continuing operations as measured by Wall Street divided by the weighted average number of common and common equivalent shares
on a diluted basis. 

	 	¿	 	 Revenue Growth in Local Currency—Net sales stated in constant local currency compared to the prior year. Specifically defined as the percentage change in annual net sales in constant local currency from
the previous fiscal year end to the current fiscal year end (“Revenue Growth”). The purpose of net sales stated in constant local currency is to remove any impact on net sales growth from changes in currency exchange rates from year to
year. 

  

  
 10 MBP    Page -1- 

	 	¿	 	 Research and Development (“R&D”) Reinvestment Rate—R&D expense as a percentage of revenue. Specifically defined as the total annual R&D expense as a percentage of annual net sales
as of the current fiscal year end. 

	 	¿	 	 Operating Income—Operating Income compared to budget may be considered for allocation of bonus pool amounts by Business Unit/Function. Operating Income is defined as Net Sales minus Cost of
Goods minus Selling and General Administrative expenses minus Research & Development minus allocated corporate interest where applicable. 

 INDIVIDUAL OBJECTIVES 
 Management Bonus Objectives (“MBOs”) are prepared by
each participant and his or her supervisor at the beginning of the Plan year and may be modified throughout the year as necessary. Objectives should reflect major results and accomplishments to be achieved in order to meet short and long-term
business goals that contribute to increased stockholder value. MBOs are expressed as specific, quantifiable measures of performance in relation to key operating decisions for the participant’s business unit, such as managing inventory levels,
receivables, expenses, payables, increasing sales, eliminating unnecessary capital expenditures, etc. 
 At the end of the Plan
year, the supervisor evaluates the participant’s performance in relation to his or her objectives in order to determine the size of the bonus award, if any. A more detailed description of how the award is calculated is provided under
“Individual Bonus Award Calculation.” 
  
  
 BONUS POOL CALCULATION 
 The
components of this calculation for the bonus pool amount are: (1) EPS, (2) Revenue Growth and (3) R&D Reinvestment Rate. 
 Bonus pool amount—Bonuses become payable when the Company achieves a threshold level
of target EPS performance. The amount of the bonus pool is determined by EPS performance, Revenue Growth and R&D Reinvestment Rate as outlined in the table below. 
  

																					
	  
 Earnings Per Share
  
	  		 	  
 Revenue Growth
  
	  		 	  
 R&D Reinvest Rate
  
	  		 	
	  
 EPS Range %
  
	 	  
 EPS Range
  
	 	  
 Bonus % of

Target
  
	  		 	  
 Revenue Growth
  
	 	  
 Bonus % of
Target
  
	  		 	  
 R&D Reinvest Rate
  
	 	  
 Bonus % of
Target
  
	  		 	  
 Bonus % of
Target
  

	 		 		 	 		 	 		 
	 -4.8%
	 	-$0.150	 	0.0%	  		 		 	 	  		 		 	 	  		 	0.0%
	 		 		 	 		 	 		 
	 -2.6%
	 	-$0.080	 	46.0%	  		 	0.4%	 	0.0%	  		 	14.75%	 	0.0%	  		 	46.0%
	 		 		 	 		 	 		 
	 -2.2%
	 	-$0.070	 	57.0%	  		 	1.4%	 	2.0%	  		 	15.00%	 	2.0%	  		 	61.0%
	 		 		 	 		 	 		 
	 -1.4%
	 	-$0.045	 	68.0%	  		 	2.4%	 	4.0%	  		 	15.25%	 	4.0%	  		 	76.0%
	 		 		 	 		 	 		 
	 -1.1%
	 	-$0.035	 	72.0%	  		 	3.4%	 	6.0%	  		 	15.50%	 	6.0%	  		 	84.0%
	 		 		 	 		 	 		 
	 -0.6%
	 	-$0.020	 	76.0%	  		 	4.4%	 	8.0%	  		 	15.75%	 	8.0%	  		 	92.0%
	 		 		 	 		 	 		 
	 	 	Target	 	80.0%	  		 	5.4%	 	10.0%	  		 	16.00%	 	10.0%	  		 	100.0%
	 		 		 	 		 	 		 
	 1.0%
	 	$0.030	 	84.0%	  		 	6.4%	 	13.8%	  		 	16.25%	 	13.8%	  		 	111.5%
	 		 		 	 		 	 		 
	 1.9%
	 	$0.060	 	88.0%	  		 	7.4%	 	17.5%	  		 	16.50%	 	17.5%	  		 	123.0%
	 		 		 	 		 	 		 
	 2.6%
	 	$0.080	 	92.0%	  		 	8.4%	 	21.3%	  		 	16.75%	 	21.3%	  		 	134.5%
	 		 		 	 		 	 		 
	 3.2%
	 	$0.100	 	96.0%	  		 	9.4%	 	25.0%	  		 	17.00%	 	25.0%	  		 	146.0%

 
 Revenue Growth and R&D Reinvestment Rate components of the
bonus pool may not exceed target unless EPS performance is equal to or greater than target. If actual results fall between the performance levels shown above, bonuses will be prorated accordingly. For sake of clarity, if the Company’s
performance exceeds any of the targets for Revenue Growth

  

  
 10 MBP    Page -2- 

 
and/or R&D Reinvestment Rate, but EPS does not exceed the threshold level of target EPS performance, no bonus will be payable. 
 BONUS POOL DIFFERENTIATION BY BUSINESS UNIT/FUNCTION 

	 	¿	 	 Operating Income—The target bonus pool determined by EPS, Revenue Growth and R&D Reinvestment Rate performance may be modified for each business unit/function based on Operating Income results vs. budget. That is, a business unit that exceeds
budget may receive a greater share of the total Company pool than a business unit that is below budget. 

 At
the end of the year, the Company’s Chief Executive Officer may recommend adjustments to the bonus pool levels to the Organization and Compensation Committee (the “Committee”) after consideration of key operating results. When
calculating corporate performance for purposes of this Plan, the Committee has the discretion to include or exclude any or all of the following items: 
  

	 	—	 	 extraordinary, unusual or non-recurring items; 

  

	 	—	 	 effects of accounting changes; 

  

	 	—	 	 effects of financing activities; 

  

	 	—	 	 expenses for restructuring or productivity initiatives; 

  

	 	—	 	 other non-operating items; 

  

	 	—	 	 spending for acquisitions; 

  

	 	—	 	 effects of divestitures; 

  

	 	—	 	 amortization of acquired intangible assets; and 

  

	 	—	 	 any other items of significant income or expense which are determined to be appropriate adjustments. 

  
  
 INDIVIDUAL BONUS AWARD CALCULATION 
 Target bonus awards are expressed as a percentage of the
participant’s year-end annualized base salary. The target percentages vary by salary grade (see Attachment No. 1). 
 A
participant’s actual bonus award may vary above or below the targeted level based on the supervisor’s evaluation of his or her performance in relation to the predetermined MBOs. Except as may otherwise be approved by the Committee, each
participant’s actual bonus award may be modified down to 0% or up to 150% of his or her target bonus amount. However, the total of all bonus awards given within each business unit must total no more than 100% of the total bonus pool dollars
allocated to that business unit. 
  
  
 METHOD OF PAYMENT 
 Except as
may otherwise be approved by the Committee, for participants who are subject to a Company executive stock ownership guideline, any bonus will be paid in cash up to a maximum amount equal to 100% of the participant’s bonus targets and the
portion of the bonus attributable to performance over such targets is paid in restricted stock or restricted stock units with cliff vesting two years from the award effective date. Any payment in the form of restricted stock or restricted stock
units will be issued under the Company’s 2008 Incentive Award Plan. Upon a recipient’s normal retirement eligibility date (defined as the date on which the recipient has (i) attained age 55 and (ii) been employed by the Company
for a minimum of 5 years) all of the

  

  
 10 MBP    Page -3- 

 
restrictions imposed on the recipient’s restricted stock shall lapse or the recipient’s restricted stock units shall vest, as applicable. 
 For all other participants, any bonus will be paid in cash. Bonus awards are paid following the close of the Plan year after the review and
authorization of bonuses by the Committee. 
 Bonuses will be paid within 30 days following management communication of the
award, with cash bonuses paid through the participant’s normal payroll channel. In the event of a Change in Control (as defined in Attachment No. 2), bonuses will be paid within 30 days of the effective date of the Change in Control.

  
  
 CHANGE IN CONTROL 
 If a Change in Control occurs after the close of the Plan
year and Company performance supports bonus pool payment, participants will be paid a bonus based on performance in relation to the EPS, Revenue Growth and R&D Reinvestment Rate targets. 
 If the Change in Control occurs during the Plan year, participants will be paid a bonus prorated to the effective date of the Change in Control and EPS, Revenue Growth and R&D
Reinvestment Rate performance will be deemed to be the greater of: 
  

	 	—	 	 100% of the EPS, Revenue Growth and R&D Reinvestment Rate targets; or 

  

	 	—	 	 the prorated actual year-to-date performance. 

 In either case, a participant’s actual bonus may vary above or below the targeted level according to the provisions outlined in “Individual Bonus Award Calculation” above. Participants must
be employed by the Company or its successor on the effective date of the Change in Control in order to receive the prorated payment, unless their employment is terminated by reason of retirement, death or disability or if it is determined that any
such participant is terminated without cause in connection with the Change in Control. For purposes of this Plan, “cause” shall be limited to only three types of events: the willful refusal to comply with a lawful, written instruction of
the Company’s Board of Directors so long as the instruction is consistent with the scope and responsibilities of the participant’s position prior to the Change in Control; dishonesty which results in a material financial loss to the
Company (or to any of its affiliated companies) or material injury to its public reputation (or to the public reputation of any of its affiliated companies); or conviction of any felony involving an act of moral turpitude. 
  
  
 SECTION 409A 
 Any bonuses that become payable under this Plan to participants who are subject to
U.S. federal income taxes are intended to be exempt from Section 409A of the Internal Revenue Code of 1986, as amended (“Section 409A”), as short-term deferrals within the meaning of Treasury Regulation section 1.409A-1(b)(4), and
this Plan shall be administered and construed consistent with this intent. For purposes of the foregoing, any bonus that becomes payable to such a participant shall be paid no later than the 15th day of the third month following the end of the later of (i) the participant’s first taxable
year in which the participant’s right to receive such bonus is no longer subject to a “substantial risk of forfeiture” (within the meaning of Section 409A) or (ii) the Company’s first taxable year in which the
participant’s right to receive such bonus is no longer subject to a substantial risk of forfeiture. 
  
  
 GENERAL 
  

  
 10 MBP    Page -4- 

 Management reserves the right to define corporate performance and individual performance, to
interpret the Plan document to make factual determinations under the Plan in its sole discretion, and to review, alter, amend, or terminate the Plan at any time subject to approval of the Committee. This Plan does not constitute a contract of
employment and cannot be relied upon as such. Any questions regarding this Plan should be directed to the Human Resources department or the Vice President, Global Compensation and Benefits. This Plan document supersedes any previous document you may
have received. 
  

  
 10 MBP    Page -5- 

 ATTACHMENT NO. 1 
  
 ALLERGAN 
  

	
	2010 MANAGEMENT BONUS PLAN

 TARGET AWARDS 
  
  

					
	Salary Grade	 	 US
 Target Bonus
	 	 Intl
 Target Bonus

			
	  7E	 	15%	 	20%
			
	  8E	 	20%	 	25%
			
	  9E	 	25%	 	30%
			
	10E	 	30%	 	35%
			
	11E	 	40%	 	40%
			
	12E	 	40%	 	45%
			
	13E	 	45%	 	50%
			
	14E	 	55%	 	
			
	15E	 	72%	 	

  

  
 10 MBP    Page -6- 

 ATTACHMENT NO. 2 
 CHANGE IN CONTROL DEFINITION 
  
 “Change in Control” shall mean the following and shall be deemed to occur if any of the following events occur: 
 (a)    Any “person,” as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)
(a “Person”), who becomes the “beneficial owner,” as defined in Rule 13d-3 under the Exchange Act or any successor rule (a “Beneficial Owner”), directly or indirectly, of securities of Allergan, Inc., a Delaware
corporation (“Allergan”) representing (i) 20% or more of the combined voting power of Allergan’s then outstanding voting securities, which acquisition is not approved in advance of the acquisition or within 30 days after the
acquisition by a majority of the Incumbent Board (as hereinafter defined) or (ii) 33% or more of the combined voting power of Allergan’s then outstanding voting securities, without regard to whether such acquisition is approved by the
Incumbent Board; or 
 (b)    Individuals who, as of the date hereof, constitute the Board
of Directors of Allergan (the “Incumbent Board”), cease for any reason to constitute at least a majority of the Board of Directors, provided that any person becoming a director subsequent to the date hereof whose election, or nomination
for election by Allergan’s stockholders, is approved by a vote of at least a majority of the directors then comprising the Incumbent Board (other than an election or nomination of an individual whose initial assumption of office is in
connection with an actual or threatened election contest relating to the election of the directors of Allergan) shall be considered as though such person were a member of the Incumbent Board of Allergan; or 
 (c)    The consummation of a merger, consolidation or reorganization involving Allergan, other than one
which satisfies both of the following conditions: 
 (1)    a merger, consolidation or
reorganization which would result in the voting securities of Allergan outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of another entity) at least 55% of the
combined voting power of the voting securities of Allergan or such other entity resulting from the merger, consolidation or reorganization (the “Surviving Corporation”) outstanding immediately after such merger, consolidation or
reorganization and being held in substantially the same proportion as the ownership in Allergan’s voting securities immediately before such merger, consolidation or reorganization, and 
 (2)    a merger, consolidation or reorganization in which no Person is or becomes the Beneficial Owner
directly or indirectly, of securities of Allergan representing 20% or more of the combined voting power of Allergan’s then outstanding voting securities; or 
 (d)    The stockholders of Allergan approve a plan of complete liquidation of Allergan or an agreement for the sale or other disposition by Allergan of all or
substantially all of Allergan’s assets. 
 Notwithstanding the preceding provisions, a Change in Control shall not be
deemed to have occurred if the Person described in the preceding provisions is (1) an underwriter or underwriting syndicate that has acquired the ownership of any of Allergan’s then outstanding voting securities solely in connection with a
public offering of Allergan’s securities, (2) Allergan or any subsidiary of Allergan or (3) an employee stock ownership plan or other employee benefit plan maintained by Allergan (or any of its affiliated companies) that is qualified
under the provisions of the Internal Revenue Code of 1986, as amended. In addition, notwithstanding the preceding provisions, a Change in Control shall not be deemed to have occurred if the Person described in the preceding provisions becomes a
Beneficial Owner of more than the permitted amount of outstanding securities as a result of the acquisition of voting securities by Allergan which, by reducing the number of voting securities outstanding, increases the proportional number of shares
beneficially owned by such Person, provided, that if a Change in Control would occur but for the operation of this sentence and such Person becomes the Beneficial Owner of any additional voting securities (other than through the grant or issuance of
securities pursuant to an award (e.g., stock option grant, restricted stock award, restricted stock unit award) granted by the Company, or through a stock dividend or stock split), then a Change in Control shall occur. 
  

  
 10 MBP    Page -7-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00169-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00169-of-00352.parquet"}]]